Primary pulmonary hypertension: genes and variants
Explore variant evidence for Primary pulmonary hypertension across 2 analyzed proteins (BMPR2, ACVRL1). Linked ClinVar records include 52 pathogenic or likely pathogenic variants, 86 variants of uncertain significance and 60 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Primary pulmonary hypertension
BMPR2: Bone morphogenetic protein receptor type-2
It initiates BMP signaling in vascular cells and helps maintain normal pulmonary-artery structure and endothelial function. Heterozygous loss-of-function variants are the most common known genetic cause of heritable pulmonary arterial hypertension.
49 ClinVar pathogenic / likely pathogenic and 146 uncertain variants in BMPR2 have source records linked to Primary pulmonary hypertension. Association strength is not clinical gene validity.
ACVRL1: Activin receptor type-1-like
It mediates BMP9 and BMP10 signaling in vascular endothelial cells and helps maintain normal vessel maturation and quiescence. Heterozygous loss-of-function variants cause hereditary hemorrhagic telangiectasia type 2, with telangiectasias and arteriovenous malformations.
3 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ACVRL1 have source records linked to Primary pulmonary hypertension. Association strength is not clinical gene validity.
Where Primary pulmonary hypertension variants cluster
- BMPR2 Extracellular (positions 27–150): 24 of 49 ClinVar pathogenic / likely pathogenic variants, 4.1× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Primary pulmonary hypertension
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| BMPR2 C117Y | 117 | Extracellular | Pathogenic / likely pathogenic (★★) |
| BMPR2 R491W | 491 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BMPR2 C496Y | 496 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BMPR2 Y67C | 67 | Extracellular | Pathogenic / likely pathogenic (★★) |
| BMPR2 N126S | 126 | Extracellular | Pathogenic / likely pathogenic (★★) |
| BMPR2 C117S | 117 | Extracellular | Pathogenic / likely pathogenic (★) |
| BMPR2 D487E | 487 | Protein kinase | Pathogenic / likely pathogenic (★) |
| BMPR2 R491L | 491 | Protein kinase | Pathogenic / likely pathogenic (★) |
| BMPR2 C496W | 496 | Protein kinase | Pathogenic / likely pathogenic (★) |
| BMPR2 C99Y | 99 | Extracellular | Pathogenic / likely pathogenic (★) |
| BMPR2 A490V | 490 | Protein kinase | Pathogenic / likely pathogenic (★) |
| BMPR2 C347R | 347 | Protein kinase | Pathogenic / likely pathogenic (★) |
| BMPR2 M449R | 449 | Protein kinase | Pathogenic / likely pathogenic (★) |
| BMPR2 C60G | 60 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 C60R | 60 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 C60Y | 60 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 C66Y | 66 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 C66G | 66 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 C66R | 66 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 C84F | 84 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 C84G | 84 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 C84R | 84 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 C117R | 117 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 C123R | 123 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 C123S | 123 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 D485G | 485 | Protein kinase | Pathogenic / likely pathogenic |
| BMPR2 D485N | 485 | Protein kinase | Pathogenic / likely pathogenic |
| BMPR2 D487V | 487 | Protein kinase | Pathogenic / likely pathogenic |
| BMPR2 C496R | 496 | Protein kinase | Pathogenic / likely pathogenic |
| BMPR2 G68D | 68 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 G83R | 83 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 C94R | 94 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 C94G | 94 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 C99F | 99 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 N124D | 124 | Extracellular | Pathogenic / likely pathogenic |
| ACVRL1 H312Q | 312 | Protein kinase | Pathogenic / likely pathogenic |
| ACVRL1 A478D | 478 | Protein kinase | Pathogenic / likely pathogenic |
| ACVRL1 R484G | 484 | Protein kinase | Pathogenic / likely pathogenic |
| BMPR2 Y113C | 113 | Extracellular | Pathogenic / likely pathogenic |
| BMPR2 K230N | 230 | Protein kinase | Pathogenic / likely pathogenic |
| BMPR2 E243Q | 243 | Protein kinase | Pathogenic / likely pathogenic |
| BMPR2 L277P | 277 | Protein kinase | Pathogenic / likely pathogenic |
| BMPR2 A313P | 313 | Protein kinase | Pathogenic / likely pathogenic |
| BMPR2 H331R | 331 | Protein kinase | Pathogenic / likely pathogenic |
| BMPR2 G426R | 426 | Protein kinase | Pathogenic / likely pathogenic |
| BMPR2 N519K | 519 | Cytoplasmic | Pathogenic / likely pathogenic |
| BMPR2 S863N | 863 | Cytoplasmic | Pathogenic / likely pathogenic |
| BMPR2 R899P | 899 | Cytoplasmic | Pathogenic / likely pathogenic |
| BMPR2 A24E | 24 | Pathogenic / likely pathogenic | |
| BMPR2 E265G | 265 | Protein kinase | Pathogenic / likely pathogenic |
| BMPR2 K982R | 982 | Cytoplasmic | Pathogenic / likely pathogenic |
| BMPR2 R10W | 10 | Pathogenic / likely pathogenic |
Uncertain variants prioritized for review in Primary pulmonary hypertension
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| BMPR2 C99R | 99 | Extracellular | Conflicting reports (★) | +7: 2 other pathogenic changes within 3 positions; C99F at the same position is pathogenic; seen in 6.6e-06 of gnomAD DNA copies; REVEL 0.942 |
| BMPR2 E243K | 243 | Protein kinase | Uncertain (★) | +7: E243Q at the same position is pathogenic; seen in 0 of gnomAD DNA copies; REVEL 0.959 |
| BMPR2 C99W | 99 | Extracellular | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; C99F at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| BMPR2 G83E | 83 | Extracellular | Uncertain (★) | +6: 4 other pathogenic changes within 3 positions; G83R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| BMPR2 G83V | 83 | Extracellular | Uncertain (★) | +6: 4 other pathogenic changes within 3 positions; G83R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| BMPR2 C60F | 60 | Extracellular | Uncertain (★) | +6: 3 other pathogenic changes within 3 positions; C60G at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.99 |
Which prediction tools work for Primary pulmonary hypertension
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 97 out of 100
- CATVariant: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 93 out of 100
- SIFT: 90 out of 100
- MetaSVM: 86 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 84 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Pulmonary arterial hypertension also has ClinVar records linked to BMPR2 variants; they fall mostly in different places as the Primary pulmonary hypertension variants (29 pathogenic / likely pathogenic).
- Hereditary hemorrhagic telangiectasia also has ClinVar records linked to ACVRL1 variants; they fall mostly in different places as the Primary pulmonary hypertension variants (180 pathogenic / likely pathogenic).
- Pulmonary arterial hypertension related to hereditary hemorrhagic telangiectasia also has ClinVar records linked to ACVRL1 variants; they fall mostly in different places as the Primary pulmonary hypertension variants (6 pathogenic / likely pathogenic).
Diseases related to Primary pulmonary hypertension
- Pulmonary arterial hypertension, also linked to ACVRL1 and BMPR2
- Hemophilia A, also linked to ACVRL1
- Hereditary hemorrhagic telangiectasia, also linked to ACVRL1
- Pulmonary arterial hypertension related to hereditary hemorrhagic telangiectasia, also linked to ACVRL1
- Pulmonary arterial hypertension associated with congenital heart disease, also linked to BMPR2
Frequently asked questions
Which genes have records linked to Primary pulmonary hypertension?
This view contains 2 analyzed proteins: BMPR2, ACVRL1. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 52 pathogenic or likely pathogenic variants, 86 variants of uncertain significance and 60 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 6 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 316 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center